Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04395222 · ClinicalTrials.gov registry record · Phase 2
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
A Phase 2 study of Hematologic Malignancy and Bone Marrow Transplant, sponsored by Weill Medical College of Cornell University.
- Active
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT04395222 is a Phase 2 study of Hematologic Malignancy and Bone Marrow Transplant that is active but no longer recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 21 participants, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04395222, a Phase 2 study of Hematologic Malignancy and Bone Marrow Transplant, is active but no longer recruiting, sponsored by Weill Medical College of Cornell University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety of reducing and ultimately eliminating anti-thymocyte globulin (ATG) from the haplo-cord transplant conditioning regimen and replacing it with tocilizumab, an IL-6 receptor monoclonal antibody, to improve immune reconstitution and reduce relapse while preserving low rates of graft failure and graft versus host disease (GVHD).
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Tocilizumab
- RADIATION Total Body Irradiation
- DRUG Anti-thymocyte globulin (rabbit)
Study Locations (1)
New York
- Weill Cornell Medical College - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-10-07 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04395222
The ClinicalTrials.gov registry entry for NCT04395222 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (91% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematologic Malignancy appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT04395222 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04395222 about?
NCT04395222 is a clinical study titled "Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation". The purpose of this study is to evaluate the safety of reducing and ultimately eliminating anti-thymocyte globulin (ATG) from the haplo-cord transplant conditioning regimen and replacing it with tocilizumab, an IL-6 receptor monoclonal antibody, to improve immune reconstitution and reduce relapse wh...
What is the current status of trial NCT04395222?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2020-10-07. Estimated completion is 2027-06.
What conditions does trial NCT04395222 study?
This clinical trial studies the following conditions: Hematologic Malignancy, Bone Marrow Transplant.
What interventions are being tested in trial NCT04395222?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Tocilizumab (DRUG), Total Body Irradiation (RADIATION), Anti-thymocyte globulin (rabbit) (DRUG).
Who is sponsoring clinical trial NCT04395222?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04395222 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
RECRUITING · Phase 2
-
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
RECRUITING · Phase 2
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
-
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
ACTIVE NOT RECRUITING · Phase 2
-
PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant
COMPLETED · Phase 2
-
FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.